New Findings on BTKi – the Tolebrutinib Study Program
At this year’s ECTRIMS Meeting in Copenhagen, the data from the study program of the Bruton-Tyrosine-Kinase (BTK) inhibitor Tolebrutinib was presented. And what can I say – fortunately there were positive news this time.
Continue reading